Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Alpine Immune Sciences Inc (NASDAQ: ALPN) closed at $64.70 in the last session, up 0.22% from day before closing price of $64.56. In other words, the price has increased by $0.22 from its previous closing price. On the day, 1.29 million shares were traded. ALPN stock price reached its highest trading level at $64.7 during the session, while it also had its lowest trading level at $64.57.
Ratios:
We take a closer look at ALPN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 7.86. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on April 09, 2024, initiated with a Buy rating and assigned the stock a target price of $55.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $44.
On October 18, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $18.Berenberg initiated its Buy rating on October 18, 2023, with a $18 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 25 ’24 when Topper James N sold 19 shares for $64.57 per share. The transaction valued at 1,227 led to the insider holds 2,829,347 shares of the business.
Rickey James Paul sold 117,764 shares of ALPN for $2,745,830 on Jan 26 ’24. The insider now owns 0 shares after completing the transaction at $23.32 per share. On Jan 25 ’24, another insider, Rickey James Paul, who serves as the insider of the company, sold 236 shares for $22.00 each. As a result, the insider received 5,192 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALPN now has a Market Capitalization of 4241764096 and an Enterprise Value of 3923336960. For the stock, the TTM Price-to-Sale (P/S) ratio is 72.03 while its Price-to-Book (P/B) ratio in mrq is 11.91. Its current Enterprise Value per Revenue stands at 66.637 whereas that against EBITDA is -89.832.
Stock Price History:
The Beta on a monthly basis for ALPN is 1.02, which has changed by 8.138418 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ALPN has reached a high of $64.70, while it has fallen to a 52-week low of $6.71. The 50-Day Moving Average of the stock is 49.19%, while the 200-Day Moving Average is calculated to be 189.90%.
Shares Statistics:
According to the various share statistics, ALPN traded on average about 2.21M shares per day over the past 3-months and 2253600 shares per day over the past 10 days. A total of 60.35M shares are outstanding, with a floating share count of 47.34M. Insiders hold about 27.77% of the company’s shares, while institutions hold 68.90% stake in the company. Shares short for ALPN as of 1713139200 were 4742079 with a Short Ratio of 2.15, compared to 1710460800 on 5610741. Therefore, it implies a Short% of Shares Outstanding of 4742079 and a Short% of Float of 11.790000000000001.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of Alpine Immune Sciences Inc (ALPN) in the stock market.On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.51, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.3 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.23 and -$1.95 for the fiscal current year, implying an average EPS of -$1.66. EPS for the following year is -$1.89, with 8.0 analysts recommending between -$1.23 and -$2.45.
